에 대한 최신 뉴스 Mynaric (OTC:MOYFF) 주식

Mynaric AG operates in the communication equipment business sector. The company is engaged in the manufacture and sale of products and projects and the provision of services in the field of laser technology, in particular in the aerospace, telematics, and satellite services sectors. It operates in two segments: Air and Space. The space segment comprises CONDOR terminals, and the Air segment comprises HAWK terminals. The company's product portfolio consists of Optical ground stations, Air-to-ground terminals, Air-to-air terminals, Space terminals, and Custom products and subcomponents. Its applications consist of high-altitude networks, remote eyes, satellite constellations, earth observation satellites, and others. Geographically, its key revenue is derived from the United States.

Mynaric AG

Barclays analyst Benjamin Theurer downgrades Lavoro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LVRO#NASDAQ">LVRO</a>) from Overweight to Underweight and lowers the price target from $5 to $1.5.

News

Downgrades

Price Target

Analyst Ratings

LVRO

Barclays Downgrades Lavoro to Underweight, Lowers Price Target to $1.5

Details of the FDA's minutes include the following, all of which will be a matter of review during the approval process:
<ul>
<li>The agency agreed to a post-NDA approval commitment of additional stability date for the 6 intermediate dose strengths of 12.5-mg, 18.75-mg, 25-mg, 31.25-mg, 37.5-mg, and 43.75-mg.</li>
<li>Cingulate expects shelf-life for all dosage strengths to be 24 months at launch, the results from the aforementioned batches may allow the shelf-life to be extended.</li>
<li>Available data for nonclinical safety appears adequate to support a filing.</li>
<li>With a scientific bridge established upon review, CTx-1301 may rely on the efficacy and safety data of the listed drug, Focalin XR.</li>
<li>Cingulate's proposed approach to the integrated safety summary (ISS) and integrated summary of efficacy (ISE) appears reasonable.</li>
</ul>

CING

Cingulate Receives Formal Pre-NDA Meeting Minutes From FDA For CTx-1301 In ADHD

WIIM

Franklin Street Properties shares are trading higher after the company announced it initiated a review of strategic alternatives.

LiqTech International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) sees Q2 sales of $4.800 million-$5.200 million vs $4.70 million analyst estimate.

Guidance

LIQT

LiqTech International Sees Q2 Sales $4.800M-$5.200M vs $4.70M Est

Sow Good (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOWG#NASDAQ">SOWG</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.11) by 109.09 percent. This is a 483.33 percent decrease over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $2.48 million which missed the analyst consensus estimate of $6.50 million by 61.89 percent. This is a 78.28 percent decrease over sales of $11.41 million the same period last year.

Earnings

Earnings Misses

SOWG

Sow Good Q1 GAAP EPS $(0.23) Misses $(0.11) Estimate, Sales $2.48M Miss $6.50M Estimate

Ratings for Rigetti Computing (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $15.0, a high estimate of $17.00, and a low estimate of $14.00. Marking an increase of 27.12%, the current average surpasses the previous average price target of $11.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1747224119_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
A clear picture of Rigetti Computing's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$14.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>David Williams</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$14.00</td>
<td>$2.50</td>
</tr>
<tr>
<td>Craig Ellis</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$8.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Rigetti Computing. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Rigetti Computing compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Rigetti Computing's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Rigetti Computing's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RGTI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Rigetti Computing analyst ratings.</a>
<h2>Get to Know Rigetti Computing Better</h2>
Rigetti Computing Inc is engaged in the business of full-stack quantum computing. The company offers full-stack quantum computing platform as a cloud service to a wide range of end-users, directly through its Rigetti QCS platform, and also through cloud service providers. Its proprietary quantum-classical infrastructure provides ultra-low latency integration with public and private clouds for high-performance practical quantum computing. The company has developed the industry's first multi-chip quantum processor for scalable quantum computing systems. Geographically, the company derives the majority of its revenue from the United States.
<h3>Rigetti Computing's Financial Performance</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Decline in Revenue: Over the 3M period, Rigetti Computing faced challenges, resulting in a decline of approximately -32.64% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Rigetti Computing's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -6726.52%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Rigetti Computing's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -122.65%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Rigetti Computing's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -69.21%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Rigetti Computing's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.07.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RGTI

Deep Dive Into Rigetti Computing Stock: Analyst Perspectives (5 Ratings)

RANI

Rani Therapeutics Holdings shares are trading higher. The company reported Q1 financial results.

Silicon Laboratories (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLAB#NASDAQ">SLAB</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $136.67, a high estimate of $160.00, and a low estimate of $80.00. Experiencing a 7.34% decline, the current average is now lower than the previous average price target of $147.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1747224095_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Silicon Laboratories. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$80.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Tore Svanberg</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Quinn Bolton</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$150.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$160.00</td>
<td>$160.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Silicon Laboratories. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Silicon Laboratories compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Silicon Laboratories's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Silicon Laboratories's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SLAB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Silicon Laboratories analyst ratings.</a>
<h2>About Silicon Laboratories</h2>
Silicon Laboratories Inc Inc is a provider of secure, intelligent wireless technology for a more connected world. The company's integrated hardware and software platform, intuitive development tools, industry ecosystem, and robust support help customers build industrial, commercial, home, and life applications. Company make it easy for developers to solve complex wireless challenges throughout the product lifecycle and get to market quickly with solutions that transform industries, grow economies, and improve lives. Company operates in USA, China, Taiwan and Rest of World, with maximum revenue from rest of the world.
<h3>Silicon Laboratories: Financial Performance Dissected</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Silicon Laboratories's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 91.43%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Information Technology sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -14.33%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Silicon Laboratories's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.2%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Silicon Laboratories's ROA excels beyond industry benchmarks, reaching -1.93%. This signifies efficient management of assets and strong financial health.
Debt Management: Silicon Laboratories's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SLAB

The Analyst Verdict: Silicon Laboratories In The Eyes Of 6 Experts

WeRide Unveils 8 Autonomous Robotaxi Pilot Operation Routes In Central Guangzhou, Establishing China's First 24-Hour Autonomous Ride-Hailing Network Covering Core Areas Of Tier 1 City

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>HC Wainwright &amp; Co. cut Annexon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) price target from $20 to $14. HC Wainwright &amp; Co. analyst Andrew Fein maintained a Buy rating. Annexon shares closed at $1.75 on Tuesday. <a href="https://www.benzinga.com/quote/ANNX/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group cut the price target for V.F. Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) from $27 to $17. Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating. V.F. Corporation shares closed at $14.95 on Tuesday. <a href="https://www.benzinga.com/quote/VFC/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Rosenblatt boosted Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) price target from $260 to $300. Rosenblatt analyst Chris Brendler maintained a Buy rating. Coinbase shares closed at $256.90 on Tuesday. <a href="https://www.benzinga.com/quote/COIN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>TD Securities raised the price target for Wingstop Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WING#NASDAQ">WING</a>) from $310 to $330. TD Securities analyst Andrew Charles maintained a Buy rating. Wingstop shares closed at $286.30 on Tuesday. <a href="https://www.benzinga.com/quote/WING/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Jefferies increased the price target for Danaos Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAC#NYSE">DAC</a>) from $100 to $105. Jefferies analyst Omar Nokta maintained a Buy rating. Danaos shares closed at $88.80 on Tuesday. See how other analysts <a href="https://www.benzinga.com/quote/DAC/analyst-ratings">view this stock</a>.</li>
<li>Needham cut Camtek Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMT#NASDAQ">CAMT</a>) price target from $110 to $80. Needham analyst Charles Shi maintained a Buy rating. Camtek shares settled at $68.61 on Tuesday. <a href="https://www.benzinga.com/quote/CAMT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham increased On Holding AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) price target from $55 to $62. Needham analyst Tom Nikic maintained a Buy rating. On Holding shares closed at $57.38 on Tuesday. <a href="https://www.benzinga.com/quote/ONON/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Chardan Capital cut MeiraGTx Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGTX#NASDAQ">MGTX</a>) price target from $38 to $35. Chardan Capital analyst Daniil Gataulin maintained a Buy rating. MeiraGTx shares closed at $5.15 on Tuesday.  <a href="https://www.benzinga.com/quote/MGTX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Jefferies increased the price target for PVH Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>) from $70 to $105. Jefferies analyst Ashley Helgans upgraded the stock from Hold to Buy. PVH shares settled at $80.50 on Tuesday. <a href="https://www.benzinga.com/quote/PVH/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners slashed iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) price target from $47 to $9. Leerink Partners analyst Daina Graybosch downgraded the stock from Outperform to Market Perform. iTeos Therapeutics shares closed at $7.85 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying COIN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14074708/image-159-1024x589.png" alt="" class="wp-image-914848" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14074708/image-159-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14074708/image-159-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14074708/image-159-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/14074708/image-159.png 1118w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/long-ideas/25/05/45375319/jim-cramer-ok-harrow-recommends-buying-this-energy-stock">Jim Cramer Is &#8216;OK&#8217; With Harrow, Recommends Buying This Energy Stock</a> </li>
</ul>
Photo via Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

ANNX

CAMT

COIN

ITOS

MGTX

NGNE

ONON

WING

Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday

LiqTech Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIQT#NASDAQ">LIQT</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.18) by 38.89 percent. This is a 24.24 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $4.62 million which beat the analyst consensus estimate of $4.50 million by 2.62 percent. This is a 9.04 percent increase over sales of $4.24 million the same period last year.

Earnings Beats

LiqTech Intl Q1 EPS $(0.25) Misses $(0.18) Estimate, Sales $4.62M Beat $4.50M Estimate

Leatt (OTC:<a class="ticker" href="https://www.benzinga.com/stock/LEAT#OTC">LEAT</a>) reported quarterly earnings of $0.17 per share. This is a 230.77 percent increase over losses of $(0.13) per share from the same period last year. The company reported $15.37 million in sales this quarter. This is a 44.79 percent increase over sales of $10.61 million the same period last year.

LEAT

Leatt Q1 EPS $0.17 Up From $(0.13) YoY, Sales $15.37M Up From $10.61M YoY

IZEA

IZEA Worldwide shares are trading higher after the company reported a year-over-year increase in Q1 EPS results. The company also announced a dutch auction tender offer to repurchase up to $8.7 million of its common stock.

In the latest quarter, 16 analysts provided ratings for PVH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PVH#NYSE">PVH</a>), showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $94.38, a high estimate of $160.00, and a low estimate of $68.00. A decline of 11.89% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1747224070_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of PVH by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$85.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$87.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$87.00</td>
<td>$91.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$103.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>Kimberly Greenberger</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$86.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Ashley Helgans</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$80.00</td>
<td>$101.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$93.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$105.00</td>
<td>$139.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$72.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$160.00</td>
<td>$172.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$128.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to PVH. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of PVH compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of PVH's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into PVH's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PVH/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on PVH analyst ratings.</a>
<h2>Get to Know PVH Better</h2>
PVH designs and markets branded apparel in more than 40 countries. Its key fashion categories include men's dress shirts, ties, sportswear, underwear, and jeans. Its two designer brands, Calvin Klein and Tommy Hilfiger, now generate practically all its revenue after its recent disposition of most of its smaller brands. PVH operates e-commerce sites, about 1,400 stores, and about 1,500 shop-in-shops and concessions. The firm also licenses its brands to third parties and distributes its merchandise through department stores and other wholesale accounts. PVH traces its history to 1881 and is based in New York City.
<h3>PVH: Financial Performance Dissected</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining PVH's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -4.75% in revenue growth, reflecting a decrease in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 6.63%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): PVH's ROE stands out, surpassing industry averages. With an impressive ROE of 3.01%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): PVH's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.41%, the company showcases efficient use of assets and strong financial health.
Debt Management: PVH's debt-to-equity ratio is below the industry average. With a ratio of 0.66, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying PVH: Insights From 16 Analyst Reviews

During the last three months, 11 analysts shared their evaluations of VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>), revealing diverse outlooks from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for VF, revealing an average target of $18.45, a high estimate of $28.00, and a low estimate of $12.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 29.85%. 
<img src="https://www.benzinga.com/files/images/story/2025/1747224059_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive VF. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$19.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Jim Duffy</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Anna Andreeva</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Neutral</td>
<td>$18.00</td>
<td>-</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$18.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Tom Nikic</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$28.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to VF. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of VF compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of VF's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into VF's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VFC/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on VF analyst ratings.</a>
<h2>About VF</h2>
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 11 brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
<h3>VF: Delving into Financials</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining VF's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.93% as of 31 December, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 5.92%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): VF's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.87% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): VF's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.47% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: VF's debt-to-equity ratio is below the industry average at 3.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What Analysts Are Saying About VF Stock

Creative Realities (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREX#NASDAQ">CREX</a>) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 1100 percent decrease over losses of $(0.01) per share from the same period last year. The company reported quarterly sales of $9.73 million which missed the analyst consensus estimate of $10.90 million by 10.70 percent. This is a 20.77 percent decrease over sales of $12.29 million the same period last year.

CREX

Creative Realities Q1 Adj. EPS $(0.12), Inline, Sales $9.73M Miss $10.90M Estimate

Across the recent three months, 6 analysts have shared their insights on Absci (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABSI#NASDAQ">ABSI</a>), expressing a variety of opinions spanning from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $8.83, a high estimate of $10.00, and a low estimate of $7.00. Surpassing the previous average price target of $8.17, the current average has increased by 8.08%.
<img src="https://www.benzinga.com/files/images/story/2025/1747224021_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Absci. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Scott Schoenhaus</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$9.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Vamil Divan</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$9.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Swayampakula Ramakanth</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>$7.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Absci. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Absci compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Absci's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Absci's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ABSI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Absci analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>About Absci</h2>
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
<h3>Breaking Down Absci's Financial Performance</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Absci's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 96.75%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Absci's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -4358.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Absci's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -15.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Absci's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -12.91%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.06.
<h2>The Significance of Analyst Ratings Explained</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABSI

Assessing Absci: Insights From 6 Financial Analysts

On May 11, 2025, Incyte Corporation (the "Company") and Novartis Pharma AG ("Novartis") entered into a settlement agreement (the "Settlement Agreement") with respect to litigation initiated by Novartis and relating to the duration of royalty payments owed by the Company to Novartis under the Collaboration and License Agreement dated November 24, 2009, as amended, between the Company and Novartis. As of March 31, 2025, the Company had approximately $537.1 million of accrued royalties relating to the dispute with Novartis included in accrued and other current liabilities on the Company's condensed consolidated balance sheet. Under the Settlement Agreement, the Company has agreed to pay to Novartis $280.0 million as the settlement of disputed royalties on net sales of JAKAFI in the United States through December 31, 2024, and the parties agreed to reduce by 50% the royalty rate payable by the Company on future net sales of JAKAFI in the United States beginning January 1, 2025 for a period defined in the Settlement Agreement. The reduced royalty payable for the quarter ended March 31, 2025, is approximately $14.9 million. The difference of $242.2 million between the total accrued royalties and the total amount to be paid by the Company to Novartis as disclosed above will be recorded in the Company's condensed consolidated statement of operations for the quarter ending June 30, 2025.

Contracts

Legal

INCY

Incyte And Novartis Settle Royalty Dispute With $280M Payment And 50% Reduction In Future JAKAFI U.S. Royalties, Resolving Litigation Over 2009 Collaboration Agreement And Releasing $242.2M In Accrued Liabilities

Leerink Partners analyst Daina Graybosch downgrades ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) from Outperform to Market Perform and lowers the price target from $47 to $9.

Leerink Partners Downgrades ITeos Therapeutics to Market Perform, Lowers Price Target to $9

Channel Therapeutics Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#NYSE">CHRO</a>) announced on Wednesday that it has achieved its predefined endpoints in two preclinical animal models for eye drop formulations (CT2000) for acute ocular and chronic ocular surface pain commonly associated <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">with dry eye disease</a>.&nbsp;
"We are very pleased with the results of these animal efficacy studies, which adds to the Depot formulation study results <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42552299/channel-therapeutics-announces-positive-efficacy-data-for-a-depot-formulation-of-a-nav1-7-inhibito" rel="noreferrer noopener">announced in December 2024</a>, demonstrating a viable path forward in treating both post-surgical pain and chronic eye pain," stated Dr. Eric Lang, Chief Medical Officer of Channel.
"Additionally, these results support our belief that the inhibition of NaV1.7 has broad applications in treating different pain indications and further supports the genetic validation that NaV1.7 is a potent target for pain," concluded Dr. Lang.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/04/44858815/exclusive-ligand-subsidiary-pelthos-therapeutics-to-combine-with-channel-therapeutics-creating-pain-medicines-focused-entity" rel="noreferrer noopener">EXCLUSIVE: Ligand Subsidiary Pelthos Therapeutics To Combine with Channel Therapeutics Creating Pain Medicines Focused Entity</a>
In the first trial, rabbits were treated with capsaicin (i.e., Pepper spray) to mimic an acute ocular insult.
<ul class="wp-block-list">
<li>Following the capsaicin treatment, the rabbits were treated with CT2000, which was dosed four times over 24 hours.</li>
<li>Pain was measured by the number of paw wipes over 60 seconds (paw wipes are a recognized surrogate of eye pain in animal models).</li>
<li>The results showed that CT2000 significantly reduced the number of paw wipes within 15 minutes of administering capsaicin and continued to show efficacy over 60 minutes following administration. </li>
</ul>
In the second trial, benzalkonium chloride (BAC) was instilled in the eyes of mice over a multiday period to create a model of dry eye disease (the study was repeated twice).
<ul class="wp-block-list">
<li>BAC is a detergent that irritates the eyes and simulates dry eye disease.</li>
<li>Following the induction of dry eye using BAC, the mice were dosed with CT2000 four times daily for seven days.</li>
<li>CT2000 reduced the frequency of paw wipes within a single day of administration and showed cumulative efficacy over time (the analgesic effect appeared to improve when dosed over several days). </li>
</ul>
"We are very encouraged with these results, and the opportunity to target a large market that currently does not have many therapeutic options could provide Channel with considerable market opportunities," stated Frank Knuettel II, CEO of Channel. "Moreover, these results pave the way for Channel to launch Phase 1/2 human proof of concept trials," Mr. Knuettel concluded.
According to Astute Analytica, the global annual chronic eye pain market was valued at $7.2 billion in 2023 and is projected to reach $12.4 billion by 2032, at a compound annual growth rate of 6.6% from 2024 to 2032.
According to Marketresearch.biz, the global annual acute eye pain market was valued at $404 million. The company intends to target this existing market with CT2000 and the postoperative pain market.
Price Action: CHRO stock closed at $1.07 on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45394076/cpi-undershoots-but-core-inflation-stays-stubborn-jp-morgan" target="_blank" rel="noreferrer noopener">CPI Undershoots But Core Inflation Stays Stubborn: JP Morgan</a></li>
</ul>
Photo via Shutterstock

Biotech

Health Care

Market-Moving Exclusives

Exclusives

General

CHRO

EXCLUSIVE: Channel Therapeutics Touts Positive Efficacy Results For Eye Treatment Potential In Multiple Preclinical In Vivo Models

Offerings

Press Releases

Mynaric Secures Another USD 5.0 million Bridge Loan to Meet Immediate Working Capital Needs

Mynaric Updates Guidance on 2024 Key Performance Indicators, Lowering Revenue and Optical Communications Terminal Backlog Guidance

Mynaric Announces Receipt of Deficiency Letters from Nasdaq

Mynaric Extends Maturity of Three Existing Bridge Loans Until February 7, 2025 and Expects Additional Bridge Loan, Restructuring Loan and Application for StaRUG Proceedings

Mynaric Secures Another USD 28 Million Bridge Loan, Extends Three Outstanding Bridge Loans, Agrees to USD 25 Million Restructuring Loan and Resolves on Reorganization Under StaRUG

Mynaric Announces Receipt of Delisting Notice from Nasdaq

Mynaric Updates on Operational Continuity and Ongoing Production and Deliveries

Management

Mynaric AG: Resignation of Bulent Altan as Chairman and Member of Supervisory Board

Mynaric Announces Peter Müller-Brühl as New Chair of Supervisory Board

Mynaric to Receive Early Partial Disbursement of Restructuring Loans Due to Delays in StaRUG Proceedings

MOYFF

MYNA

MYNAY

Mynaric

Comments

Mynaric

뉴스

에 대한 최신 뉴스 Mynaric (OTC:MOYFF) 주식

뉴스

파트너 / 기고자

벤징가 글로벌